XmAb 143
Alternative Names: XmAb-143Latest Information Update: 07 Jun 2022
At a glance
- Originator Xencor
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Interleukin 18 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Apr 2022 Efficacy and Pharmacokinetics data from a preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022) (Xencor website, April 2022)
- 12 Apr 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022) (Xencor website, April 2022)
- 08 Apr 2022 Preclinical trials for cancer in Unknown country before April 2022 (Parenteral) (Xencor website, April 2022)